Jonathan Rosand Selected Research

Genie

1/2023	The relevance of rich club regions for functional outcome post-stroke is enhanced in women.
1/2021	Excessive White Matter Hyperintensity Increases Susceptibility to Poor Functional Outcomes After Acute Ischemic Stroke.
1/2020	Diffusion-Weighted Imaging, MR Angiography, and Baseline Data in a Systematic Multicenter Analysis of 3,301 MRI Scans of Ischemic Stroke Patients-Neuroradiological Review Within the MRI-GENIE Study.
1/2019	Big Data Approaches to Phenotyping Acute Ischemic Stroke Using Automated Lesion Segmentation of Multi-Center Magnetic Resonance Imaging Data.
1/2019	White matter hyperintensity quantification in large-scale clinical acute ischemic stroke cohorts - The MRI-GENIE study.
10/2017	Design and rationale for examining neuroimaging genetics in ischemic stroke: The MRI-GENIE study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonathan Rosand Research Topics

Disease

71	Cerebral Hemorrhage 03/2024 - 07/2003
43	Stroke (Strokes) 12/2023 - 08/2005
31	Ischemic Stroke 03/2024 - 07/2008
25	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2023 - 11/2004
20	Hemorrhage 08/2020 - 04/2004
18	Hematoma 01/2021 - 12/2005
10	Atrial Fibrillation 01/2021 - 07/2003
8	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021 - 11/2004
7	Hypertension (High Blood Pressure) 01/2021 - 05/2010
6	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 11/2008
6	Brain Injuries (Brain Injury) 01/2022 - 07/2015
6	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2021 - 04/2012
5	Cardiovascular Diseases (Cardiovascular Disease) 12/2023 - 01/2019
5	Cerebral Small Vessel Diseases 10/2023 - 03/2015
5	Venous Thrombosis (Deep-Vein Thrombosis) 08/2022 - 01/2009
5	Critical Illness (Critically Ill) 01/2021 - 05/2017
5	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2021 - 07/2015
5	Dementia (Dementias) 01/2019 - 07/2012
4	Coronary Artery Disease (Coronary Atherosclerosis) 12/2023 - 05/2010
4	Hemorrhagic Stroke 01/2022 - 09/2007
4	Inflammation (Inflammations) 10/2020 - 12/2010
4	Genetic Risk Score 01/2020 - 01/2014
4	Siderosis 01/2020 - 03/2015
4	Disease Progression 01/2019 - 08/2011
4	Embolic Stroke 11/2018 - 04/2004
4	Familial Cerebral Amyloid Angiopathy 10/2016 - 07/2008
4	Cognitive Dysfunction 04/2013 - 11/2004
3	Atherosclerosis 12/2023 - 01/2017
3	Peripheral Arterial Disease 12/2023 - 01/2022
3	Diabetes Mellitus 08/2023 - 04/2004
3	Leukoencephalopathies 01/2022 - 04/2013
3	Lacunar Stroke 01/2021 - 03/2016
3	COVID-19 01/2021 - 06/2020
3	Edema (Dropsy) 10/2020 - 12/2005
3	Infections 05/2017 - 01/2004
3	Infarction (Infarctions) 12/2015 - 05/2008
2	Myocardial Infarction 03/2024 - 01/2022
2	Chronic Renal Insufficiency 08/2023 - 01/2020
2	Epilepsy (Aura) 07/2023 - 05/2023
2	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2021 - 07/2008
2	Thromboembolism 01/2020 - 12/2008
2	Brain Concussion (Cerebral Concussion) 01/2018 - 01/2017
2	Craniocerebral Trauma (Head Injury) 01/2018 - 01/2016
2	CADASIL 01/2016 - 07/2008
2	Leukoaraiosis 08/2014 - 04/2013
1	Neoplasms (Cancer) 01/2023

Drug/Important Bio-Agent (IBA)

21	Apolipoproteins E (ApoE)IBA 12/2021 - 12/2010
20	Warfarin (Coumadin)FDA LinkGeneric 01/2018 - 07/2003
14	Amyloid (Amyloid Fibrils)IBA 01/2023 - 11/2004
13	AnticoagulantsIBA 01/2023 - 07/2003
12	Biomarkers (Surrogate Marker)IBA 12/2022 - 11/2014
12	ApolipoproteinsIBA 09/2022 - 06/2012
10	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 12/2005
7	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2024 - 07/2008
6	GenieIBA 01/2023 - 10/2017
5	LipidsIBA 01/2022 - 07/2015
5	danaparoid (Orgaran)FDA Link 01/2019 - 05/2011
4	CholesterolIBA 01/2021 - 03/2010
4	Amyloid beta-PeptidesIBA 11/2008 - 12/2005
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022 - 08/2016
3	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 08/2010
3	ORALIT (ORS)IBA 01/2021 - 06/2010
3	Blood Glucose (Blood Sugar)IBA 01/2020 - 05/2008
3	CalciumIBA 01/2019 - 11/2016
3	Genetic Markers (Genetic Marker)IBA 01/2018 - 12/2008
3	HomocysteineIBA 03/2016 - 05/2010
3	Anticonvulsants (Antiepileptic Drugs)IBA 12/2015 - 12/2012
3	Hemostatics (Antihemorrhagics)IBA 11/2014 - 01/2012
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 10/2014 - 11/2004
3	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 04/2013 - 11/2008
3	Factor VIIa (Activated Factor VII)IBA 11/2006 - 12/2005
2	Interleukin-6 (Interleukin 6)IBA 12/2023 - 03/2023
2	InterferonsIBA 12/2023 - 03/2023
2	Chemokine CXCL10IBA 12/2023 - 03/2023
2	Valproic Acid (Depakote)FDA LinkGeneric 07/2023 - 05/2023
2	LDL CholesterolIBA 01/2022 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 08/2015
2	AlbuminsIBA 01/2020 - 05/2017
2	oxidized low density lipoproteinIBA 01/2020 - 08/2016
2	CreatinineIBA 01/2020 - 01/2018
2	P-2 (P 2)IBA 04/2017 - 12/2015
2	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 01/2017 - 01/2016
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2017 - 01/2004
2	Vitamin K FDA Link 07/2015 - 01/2006
2	Collagen Type IV (Type IV Collagen)IBA 04/2012 - 07/2008
1	Proteins (Proteins, Gene)FDA Link 12/2023
1	ChemokinesIBA 12/2023
1	LigandsIBA 12/2023
1	PolyaminesIBA 10/2023
1	Clopidogrel (Plavix)FDA Link 08/2023
1	Cytochrome P-450 CYP2C19IBA 08/2023

Therapy/Procedure

21	Therapeutics 01/2023 - 07/2003
3	Secondary Prevention 08/2023 - 03/2016
2	Minimally Invasive Surgical Procedures 01/2022 - 11/2020
2	Precision Medicine 01/2022 - 01/2019
2	Artificial Respiration (Mechanical Ventilation) 01/2021 - 08/2013
2	Ambulatory Care (Outpatient Care) 01/2021 - 06/2020
2	Critical Care (Surgical Intensive Care) 12/2019 - 01/2007
1	Vascular Surgical Procedures 03/2024
1	Percutaneous Coronary Intervention 08/2023